Michael B. Atkins, MD - Choosing Innovation With Immunotherapy in Melanoma: Guidance on Utilizing Immune-Based and Other Novel Options in Resectable and Unresectable Disease

Go online to PeerView.com/NDA860 to view the activity, download
slides and practice aids, and complete the post-test to earn
credit. Patients with severe asthma, uncontrolled symptoms, and
exacerbations are at risk of losing lung function over time.
Despite the availability of numerous treatments, many patients with
severe asthma remain uncontrolled. Evolving insights into the
pathophysiology of severe asthma have led to the development of
biologic therapies that target epithelial alarmins, and their use
is not restricted by phenotype/endotype or biomarkers. In this
activity, based on a recent live web broadcast, our experts will
review the latest clinical data, including key insights from
medical congresses up to and including ATS 2022, with respect to
novel and emerging therapies and other factors that impact the
selection of treatment for patients with severe asthma who continue
to have uncontrolled disease despite treatment. You will achieve
greater insight into the most up-to-date evidence on the
pathophysiology of severe asthma, particularly with regard to the
role of epithelial alarmins in the development of severe asthma.
Upon completion of this activity, participants should be better
able to: Discuss the rationale for the use of therapeutic options
that target epithelial alarmins, including TSLP, IL-33, and IL-25,
for the treatment of severe asthma; Employ the latest
pathophysiologic insights into the role of epithelial alarmins to
the treatment of patients with severe asthma; and Develop treatment
plans for patients with severe asthma, particularly those whose
disease remains uncontrolled despite treatment, based on the latest
clinical evidence with regard to novel and emerging therapies.